Company Overview of Reliance Life Sciences Pvt. Ltd.
Reliance Life Sciences Pvt. Ltd. operates as a life sciences company. Its activities include researching, developing, and marketing plasma proteins, biosimilars, and proteins; developing active pharmaceutical ingredients and formulations, such as oncology products, steroids, hormones, and peptides; offering services, which include regulatory toxicity studies, bioavailability, pharmacokinetics, cardiac safety, mass balance studies, phase I to IV clinical trial management and monitoring, data management and biostatistics, and medical writing; and providing regenerative medicine, which include embryonic stem cells, ocular stem cells, haematopoietic stem cells, skin and tissue engineering, and a...
Dhirubhai Ambani Life Sciences Centre
R-282, TTC Area of MIDC
Navi Mumbai, 400 701
Founded in 2001
Key Executives for Reliance Life Sciences Pvt. Ltd.
Chief Executive Officer and President
President of U S Operations
General Manager of Corporate Communications
Compensation as of Fiscal Year 2017.
Reliance Life Sciences Pvt. Ltd. Key Developments
Reliance Lifesciences Launches First Biosimilar Used to Treat Advanced Cancers
Jun 11 16
Reliance Lifesciences has launched the biosimilar, or copies of bevacizumab, a complex medicine used to treat at least six forms of advanced cancers. Reliance's product is approved by the Indian regulator for use in cases of colorectal cancer. Swiss biotechnology powerhouse Roche is the innovator of bevacizumab and markets it globally as Avastin. The product had annual sales in excess of $7 billion last year. While Reliance will market the bevacizumab copies under its own brand name Bevacirel, it has also entered into a "principal-to-principal agreement" with Lupin. It had introduced a recombinant chorionic gonadotrophin hormone used in assisted reproduction, interferon beta for the treatment of multiple sclerosis, and reteplase, a drug used in the management of myocardial infarction. A Reliance official declined to comment on the development. Lupin did not respond uuntil the time of going to press. Reliance's bevacizumab is expected to compete with Roche's brand, but unlike most biosimilar launches, where the cut price versions are sold at roughly 25% discount over the innovator's price, market sources said Reliance has kept a minuscule gap between the price of its product and that of Roche. Roche's Avastin of 100 mg strength is learnt to be sold at about INR 29,500 while Reliance is likely to market its product at INR 28,300 per injection. For the 400 mg variant, Avastin is available at about INR 108,000 and Reliance's drug is sold at INR 105,000 for each injection. Market sources estimated the market at about INR 1,700, but added that a wider market footprint of Lupin and Reliance will accelerate the reach.
Delhi High Court Places Temporary Injunction Preventing Sales of Reliance's Biosimilar Trastuzumab
Nov 4 15
The Indian Delhi High Court has issued a temporary injunction banning Reliance (India) from launching a "biosimilar" version of Roche (Switzerland)'s breast cancer drug Herceptin (trastuzumab). The injunction follows a petition filed by Roche, which argues that Reliance's product is similar to Herceptin. The two companies have now been requested to submit written submissions within two weeks before the court is to hear the case.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|